Get the latest tech news
Kidney Cancer Vaccine Shows Promise in Early Trial
The vaccine generated robust immune response in nine patients with advanced disease
In a small clinical trial of nine patients with advanced kidney cancer, a personalized vaccine generated robust immune response. Such early-stage trials are designed to determine the safety and optimal dosage of a treatment and to establish whether and how well patients respond to the therapy before further testing in more people. Additional authors include Derin Keskin, immunologist at the Center for Cancer Vaccines at Dana-Farber, and David A. Braun, formerly of Dana-Farber and Harvard Medical School and now a medical oncologist and physician-scientist at Yale Cancer Center and Yale School of Medicine, who is first author.
Or read this on r/technology